Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | STING1 | Q86WV6 | 7/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.40 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16368336 | 0.88 | KRAS (0.53) | STING1P2RY2KRAS | |
| SCHEMBL19986613 | 0.88 | KRAS (0.53) | STING1P2RY2KRAS | |
| SCHEMBL16367960 | 0.86 | IMPDH2 (0.43) | P2RX3ADORA3P2RX1P2RY2P2RY1 | |
| SCHEMBL16490110 | 0.86 | P2RX1 (0.57) | P2RX3P2RX1P2RX2P2RY2P2RY1 | |
| SCHEMBL15070748 | 0.86 | P2RX1 (0.57) | P2RX3P2RX1P2RX2P2RY2P2RY1 | |
| SCHEMBL15070345 | 0.85 | P2RX3 (0.42) | P2RX3P2RX1P2RX2P2RY2P2RY1 | |
| SCHEMBL17359754 | 0.81 | POLG (0.51) | STING1P2RY2P2RY1KRAS | |
| SCHEMBL16373906 | 0.81 | POLG (0.51) | STING1P2RY2P2RY1KRAS | |
| SCHEMBL18672020 | 0.80 | POLG (0.51) | STING1P2RY2KRAS | |
| SCHEMBL17359759 | 0.80 | POLG (0.51) | STING1P2RY2KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | P2RX3 90/4885ADORA3 53/4885STING1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.